Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

KPV

Lys-Pro-Val, α-MSH (11-13)

Quick Stats
Studies 104
Trials 57
Score 1
2023 pubmed 28 citations

The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials.

Gravina. Antonietta Gerarda AG; Pellegrino. Raffaele R; Durante. Tommaso T; Palladino. Giovanna G; Imperio. Giuseppe G; D'Amico. Giovanbattista G; Trotta. Maria Consiglia MC; Dallio. Marcello M; Romeo. Mario M; D'Amico. Michele M; Federico. Alessandro A

Key Findings

  • Melanocortin receptors influence inflammation in the gut
  • Mouse studies show activating this system reduces colitis symptoms
  • Targeting melanocortin pathways is proposed as a future IBD therapy

Practical Outcomes

  • At this stage there’s nothing biohackers can directly apply—no dosage, supplement, or safe self‑experiment is described. Keep an eye on emerging drugs that act on melanocortin receptors, but for now it’s mainly a research insight rather than a usable protocol.

Summary

A review says the body’s melanocortin system can calm gut inflammation in mouse models of IBD, and drugs that tweak this system might someday help treat Crohn’s or ulcerative colitis, but there’s no ready‑to‑use supplement or protocol for people now.

Abstract

The melanocortin system is a complex set of molecular mediators and receptors involved in many physiological and homeostatic processes. These include the regulation of melanogenesis, steroidogenesis, neuromodulation and the modulation of inflammatory processes. In the latter context, the system has assumed importance in conditions of chronic digestive inflammation, such as inflammatory bowel diseases (IBD), in which numerous experiences have been accumulated in mouse models of colitis. Indeed, information on how such a system can counteract colitis inflammation and intervene in the complex cytokine imbalance in the intestinal microenvironment affected by chronic inflammatory damage has emerged. This review summarises the evidence acquired so far and highlights that molecules interfering with the melanocortin system could represent new drugs for treating IBD.

Study Information

Provider

pubmed

Year

2023

Date

2023-07-19T00:00:00.000Z

DOI

10.3390/cells12141889

Citations

28

References

110